A recent study of 230 patients with sarcomatoid renal cell carcinoma (RCC) investigated pre-surgery neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, and platelet-lymphocyte ratio as biomarkers for the prediction of survival. Neutrophil-lymphocyte ratio was assessed 1 to 8 weeks after surgery, and percentage change from pre- to post-surgery was calculated.
Pre-surgery neutrophil-lymphocyte ratio was a significant predictor of cancer-specific survival for people with metastatic and locally advanced sarcomatoid RCC. For metastatic patients, pre-surgery neutrophil-lymphocyte ratio was significantly associated with survival; however, change in neutrophil-lymphocyte ratio was not associated with outcome.
In conclusion, pre-surgery neutrophil-lymphocyte ratio is associated with cancer-specific survival in locally advanced and metastatic sarcomatoid RCC. Neutrophil-lymphocyte ratio should be considered when establishing future predictive models for sarcomatoid RCC.